The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice

Epilepsy and Behavior

Volumn 28, Issue 1, 2013, Pages 1-7

  Shirazi zand, Zahra ^a   Ahmad Molaei, Leila ^a   Motamedi, Fereshteh ^a   Naderi, Nima ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cannabidiol; Maximal electroshock; Paxilline; Pentylenetetrazole; Seizure

Indexed keywords

CANNABIDIOL; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; PAXILLINE; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; ELECTRIC SHOCK; MALE; MOUSE; MYOCLONUS SEIZURE; NONHUMAN; SEIZURE; SEIZURE THRESHOLD; TONIC SEIZURE;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; CANNABIDIOL; CONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; INDOLES; INJECTIONS, INTRAVENTRICULAR; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MALE; MICE; PENTYLENETETRAZOLE; POTASSIUM CHANNEL BLOCKERS; SEIZURES;

EID: 84877349075     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.03.009     Document Type: Article

References (84)

1. 2+ levels. J Neurosci 2009, 29:2053-2063.
2. Michoulam R., Shvo Y., Hashish I. The structure of cannabidiol. Tetrahedron 1963, 19:2073-2078.
3. Gordon E., Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001, 42:1266-1272.
4. Ellison J.M., Gelwan E., Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatry 1990, 51:439-440.
5. Consroe P.F., Wood G.C., Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA 1975, 234:306-307.
6. Perez-Reyes M., Timmons M.C., Lipton M.A., Christensen H.D., Davis K.H., Wall M.E. A comparison of the pharmacological activity of delta 9-tetrahydrocannabinol and its monohydroxylated metabolites in man. Experientia 1973, 29:1009-1010.
7. Hollister L.E. Cannabidiol and cannabinol in man. Experientia 1973, 29:825-826.
8. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21:175-185.
9. Benowitz N.L., Nguyen T.L., Jones R.T., Herning R.I., Bachman J. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 1980, 28:115-120.
10. Pertwee R. The pharmacology and therapeutic potential of cannabidiol 2004, Kluwer Academic/Plenum Publishers ed, London.
11. Guimaraes F.S., de Aguiar J.C., Mechoulam R., Breuer A. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 1994, 25:161-164.
12. Carrier E.J., Auchampach J.A., Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 2006, 103:7895-7900.
13. Drysdale A.J., Platt B. Cannabinoids: mechanisms and therapeutic applications in the CNS. Curr Med Chem 2003, 10:2719-2732.
14. Leweke F.M., Schneider U., Radwan M., Schmidt E., Emrich H.M. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav 2000, 66:175-181.
15. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 2005, 19:96-107.
16. Esposito G., De Filippis D., Maiuri M.C., De Stefano D., Carnuccio R., Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006, 399:91-95.
17. Iuvone T., Esposito G., Esposito R., Santamaria R., Di Rosa M., Izzo A.A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004, 89:134-141.
18. Bhattacharyya S., Fusar-Poli P., Borgwardt S., Martin-Santos R., Nosarti C., O'Carroll C., et al. Modulation of mediotemporal and ventrostriatal function in humans by delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009, 66:442-451.
19. Jones N.A., Hill A.J., Smith I., Bevan S.A., Bevan S.A., Williams C.M., et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2009, 332:569-577.
20. Wallace M.J., Wiley J.L., Martin B.R., DeLorenzo R.J. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 2001, 428:51-57.
21. Hayase T., Yamamoto Y., Yamamoto K. Protective effects of cannabinoid receptor ligands analogous to anandamide against cocaine toxicity. Nihon Arukoru Yakubutsu Igakkai Zasshi 2001, 36:596-608.
22. Usami N., Kobana K., Yoshida H., Kimura T., Watanabe K., Yoshimura H., et al. Synthesis and pharmacological activities in mice of halogenated delta 9-tetrahydrocannabinol derivatives. Chem Pharm Bull(Tokyo) 1998, 46:1462-1467.
23. Karler R., Murphy V., Calder L.D., Turkanis S.A. Pentylenetetrazol kindling in mice. Neuropharmacology 1989, 28:775-780.
24. Turkanis S.A., Chiu P., Borys H.K., Karler R. Influence of delta9-tetrahydrocannabinol and cannabidiol on photically evoked after-discharge potentials. Psychopharmacology (Berl) 1977, 52:207-212.
25. Chesher G.B., Jackson D.M. Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia 1974, 37:255-264.
26. Consroe P., Martin A., Singh V. Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol 1981, 21:428S-436S.
27. Karler R., Turkanis S.A. The cannabinoids as potential antiepileptics. J Clin Pharmacol 1981, 21:437S-448S.
28. Consroe P., Benedito M.A., Leite J.R., Carlini E.A., Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982, 83:293-298.
29. Sim-Selley L.J., Martin B.R. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-b enzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 2002, 303:36-44.
30. Vergara C., Latorre R., Marrion N.V., Adelman J.P. Calcium-activated potassium channels. Curr Opin Neurobiol 1998, 8:321-329.
31. Sah P., McLachlan E.M. Potassium currents contributing to action potential repolarization and the afterhyperpolarization in rat vagal motoneurons. J Neurophysiol 1992, 68:1834-1841.
32. Marty A. The physiological role of calcium-dependent channels. Trends Neurosci 1989, 12:420-424.
33. Blatz A.L., Magleby K.L. Ion conductance and selectivity of single calcium-activated potassium channels in cultured rat muscle. J Gen Physiol 1984, 84:1-23.
34. + channel beta-subunit from human brain. Proc Natl Acad Sci U S A 1996, 93:9200-9205.
35. + (BK) channel inactivation contributes to spike broadening during repetitive firing in the rat lateral amygdala. J Physiol 2003, 552:483-497.
36. + channels in spike broadening during repetitive firing in rat hippocampal pyramidal cells. J Physiol 1999, 521(Pt. 1):135-146.
37. + channels in glutamatergic hippocampal terminals and their role in spike repolarization and regulation of transmitter release. J Neurosci 2001, 21:9585-9597.
38. Raffaelli G., Saviane C., Mohajerani M.H., Pedarzani P., Cherubini E. BK potassium channels control transmitter release at CA3-CA3 synapses in the rat hippocampus. J Physiol 2004, 557:147-157.
39. + channels in cerebellar Purkinje neurons. Eur J Neurosci 2002, 16:1214-1222.
40. Schwindt P.C., Spain W.J., Foehring R.C., Stafstrom C.E., Chubb M.C., Crill W.E. Multiple potassium conductances and their functions in neurons from cat sensorimotor cortex in vitro. J Neurophysiol 1988, 59:424-449.
41. 2+ chelator inhibits spike repolarization in hippocampal neurons. Brain Res 1987, 435:387-392.
42. Storm J.F. Action potential repolarization and a fast after-hyperpolarization in rat hippocampal pyramidal cells. J Physiol 1987, 385:733-759.
43. Lancaster B., Nicoll R.A. Properties of two calcium-activated hyperpolarizations in rat hippocampal neurones. J Physiol 1987, 389:187-203.
44. + current in vertebrate sympathetic neurones. Nature 1982, 296:746-749.
45. Alger B.E., Williamson A. A transient calcium-dependent potassium component of the epileptiform burst after-hyperpolarization in rat hippocampus. J Physiol 1988, 399:191-205.
46. Du W., Bautista J.F., Yang H., Diez-Sampedro A., You S.A., Wang L., et al. Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder. Nat Genet 2005, 37:733-738.
47. Brenner R., Chen Q.H., Vilaythong A., Toney G.M., Noebels J.L., Aldrich R.W. BK channel beta4 subunit reduces dentate gyrus excitability and protects against temporal lobe seizures. Nat Neurosci 2005, 8:1752-1759.
48. Gu N., Vervaeke K., Storm J.F. BK potassium channels facilitate high-frequency firing and cause early spike frequency adaptation in rat CA1 hippocampal pyramidal cells. J Physiol 2007, 580:859-882.
49. Storm J.F., Sartorius T., Gu N., Sausbier M., Sausbier U., Ruth P. Alterations in cortical EEG activity, neuronal excitability and sleep-wake behavior in BK channel-deficient mice. Abstr Soc Neurosci 2006, 627.9:D23-D.
50. Knaus H.G., McManus O.B., Lee S.H., Schmalhofer W.A., Garcia-Calvo M., Helms L.M., et al. Tremorgenic indole alkaloids potently inhibit smooth muscle high-conductance calcium-activated potassium channels. Biochemistry 1994, 33:5819-5828.
51. Sanchez M., McManus O.B. Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology 1996, 35:963-968.
52. Paxinos G., Franklin KBJ The mouse brain in stereotaxic coordinates 2008, Academic Press, New York. 3rd ed.
53. Holmes G.L., Zhao Q. Choosing the correct antiepileptic drugs: from animal studies to the clinic. Pediatr Neurol 2008, 38:151-162.
54. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949, 96:99-113.
55. Gennings C., Carter W.H., Campbell E.D., Staniswalis J.G., Martin T.J., Martin B.R., et al. Isobolographic characterization of drug interactions incorporating biological variability. J Pharmacol Exp Ther 1990, 252:208-217.
56. Scuderi C., Filippis D.D., Iuvone T., Blasio A., Steardo A., Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 2009, 23:597-602.
57. Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol 2004, 68:1691-1698.
58. Carlini E.A., Leite J.R., Tannhauser M., Berardi A.C. Letter: cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 1973, 25:664-665.
59. Wanner S.G., Koch R.O., Koschak A., Trieb M., Garcia M.L., Kaczorowski G.J., et al. High-conductance calcium-activated potassium channels in rat brain: pharmacology, distribution, and subunit composition. Biochemistry 1999, 38:5392-5400.
60. + channels in rat brain: targeting to axons and nerve terminals. J Neurosci 1996, 16:955-963.
61. Sheehan J.J., Benedetti B.L., Barth A.L. Anticonvulsant effects of the BK-channel antagonist paxilline. Epilepsia 2009, 50:711-720.
62. Shruti S., Clem R.L., Barth A.L. A seizure-induced gain-of-function in BK channels is associated with elevated firing activity in neocortical pyramidal neurons. Neurobiol Dis 2008, 30:323-330.
63. Fragoso-Veloz J., Massieu L., Alvarado R., Tapia R. Seizures and wet-dog shakes induced by 4-aminopyridine, and their potentiation by nifedipine. Eur J Pharmacol 1990, 178:275-284.
64. Segal M., Rogawski M.A., Barker J.L. A transient potassium conductance regulates the excitability of cultured hippocampal and spinal neurons. J Neurosci 1984, 4:604-609.
65. Brew H.M., Gittelman J.X., Silverstein R.S., Hanks T.D., Demas V.P., Robinson L.C., et al. Seizures and reduced life span in mice lacking the potassium channel subunit Kv1.2, but hypoexcitability and enlarged Kv1 currents in auditory neurons. J Neurophysiol 2007, 98:1501-1525.
66. Castaldo P., del Giudice E.M., Coppola G., Pascotto A., Annunziato L., Taglialatela M. Benign familial neonatal convulsions caused by altered gating of KCNQ2/KCNQ3 potassium channels. J Neurosci 2002, 22:RC199.
67. Rho J.M., Szot P., Tempel B.L., Schwartzkroin P.A. Developmental seizure susceptibility of kv1.1 potassium channel knockout mice. Dev Neurosci 1999, 21:320-327.
68. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 1991, 8:171-189.
69. 2+ elevations in hippocampal cells. Neuropharmacology 2006, 50:621-631.
70. Kaplan B.L., Rockwell C.E., Kaminski N.E. Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J Pharmacol Exp Ther 2003, 306:1077-1085.
71. 2+ signals in cerebellar granule neurons in culture. J Neurosci 1999, 19:8765-8777.
72. Shen M., Thayer S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998, 54:459-462.
73. Shohami E., Gallily R., Mechoulam R., Bass R., Ben-Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 1997, 72:169-177.
74. Nadler V., Biegon A., Beit-Yannai E., Adamchik J., Shohami E. 45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211. Brain Res 1995, 685:1-11.
75. Eshhar N., Striem S., Kohen R., Tirosh O., Biegon A. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol 1995, 283:19-29.
76. Shohami E., Novikov M., Mechoulam R. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J Neurotrauma 1993, 10:109-119.
77. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997, 78:43-50.
78. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 1992, 89:3825-3829.
79. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 1992, 106:231-232.
80. Robbe D., Alonso G., Duchamp F., Bockaert J., Manzoni O.J. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 2001, 21:109-116.
81. Hampson R.E., Mu J., Deadwyler S.A. Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons. J Neurophysiol 2000, 84:2356-2364.
82. Venance L., Piomelli D., Glowinski J., Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 1995, 376:590-594.
83. 2+ influx via TRPV1 channels. EMBO J 2005, 24:3026-3037.
84. Brenowitz S.D., Regehr W.G. Calcium dependence of retrograde inhibition by endocannabinoids at synapses onto Purkinje cells. J Neurosci 2003, 23:6373-6384.